Hepatitis C virus therapy update 2013

LC Casey, WM Lee - Current opinion in gastroenterology, 2013 - journals.lww.com
LC Casey, WM Lee
Current opinion in gastroenterology, 2013journals.lww.com
The standard of care for treatment of HCV genotype 1 changed dramatically with the
approval of two new DAA drugs–telaprevir and boceprevir–for use in pegylated interferon-
based and ribavirin-based triple therapy in mid-2011. Experience has shown improved
response rates and treatment durations for many patients with genotype 1 HCV infection.
However, persistent limitations to HCV treatment still exist for patients with prior treatment
failure and comorbid conditions and patients on newer therapies suffer additional therapy …
Summary
The standard of care for treatment of HCV genotype 1 changed dramatically with the approval of two new DAA drugs–telaprevir and boceprevir–for use in pegylated interferon-based and ribavirin-based triple therapy in mid-2011. Experience has shown improved response rates and treatment durations for many patients with genotype 1 HCV infection. However, persistent limitations to HCV treatment still exist for patients with prior treatment failure and comorbid conditions and patients on newer therapies suffer additional therapy-limiting side effects and drug–drug interactions. Genetic testing may provide some guidance but additional options for therapy are still needed for HCV. Many new drugs are currently under investigation and there is hope that effective and well tolerated interferon-free regimens may become a part of future therapy.
Lippincott Williams & Wilkins